PCM
COGT icon

Peregrine Capital Management’s Cogent Biosciences COGT Stock Holding History

Peregrine Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76M Buy
226,350
+24,391
+12% +$853K 0.28% 108
2026
Q1 		$7.77M Buy
+201,959
New +$7.46M 0.29% 106

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Peregrine Capital Management's COGT Position: Q2 2026 in Review

Peregrine Capital Management increased its Cogent Biosciences (COGT) stake by 12% in Q2 2026, buying an estimated $853K and bringing the position to 226,350 shares worth $8.76M. The position accounts for 0.28% of the portfolio, ranked #108.

Peregrine Capital Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Peregrine Capital Management held 226,350 shares of Cogent Biosciences worth $8.76M as of Q2 2026.
  • Peregrine Capital Management bought 24,391 Cogent Biosciences shares in Q2 2026, an estimated $853K.
  • Cogent Biosciences made up 0.28% of Peregrine Capital Management's portfolio in Q2 2026, its #108 holding.
  • Peregrine Capital Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.